Non-Small-Cell Lung Carcinoma
Conditions
Keywords
NSCLC
Brief summary
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG4010 is intended to induce a MUC1-specific cellular immune response and to produce a non-specific activation of several components of the immune system.
Interventions
BIOLOGICALTG4010
TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason. Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles. First line therapy: * Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab * Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin Maintenance therapy: • Pemetrexed or erlotinib for eligible patients and according to labeling.
DRUGplacebo
Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason. * First line therapy: as in Arm 1 * Maintenance therapy: as in Arm 1
Sponsors
Transgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other) * Stage IV cancer according to TNM classification (7th edition - UICC, December 2009; includes tumor with malignant pleural or pericardial effusion * Tumor biopsy specimen with ≥ 50% of MUC1 expressing tumor cells determined by Immunohistochemistry (IHC) staining on fixed pathological material. Biopsy may come either from the primary tumor or from a metastasis. Cytological material is not accepted for this analysis * Patient's naïve to first-line therapy for the advanced stage of the disease. Previous neoadjuvant or adjuvant therapy is allowed for patients who successfully underwent complete radical surgery and if last treatment was administered more than 12 months prior to the start of the study treatment, i.e., D1 of Cycle 1. * At least one measurable lesion by CT scan or MRI based on RECIST version 1.1 * PS 0 or 1 on the ECOG scale * Adequate hematological, hepatic, and renal function: * Hemoglobin ≥ 10.0 g/dL * White Blood Cells (WBC) ≥ 3.0x10E9/L including * Neutrophils ≥ 1.5x109/L * Total lymphocytes count ≥ 0.5x10E9/L * Platelets count ≥ 100x10E9/L * Serum alkaline phosphatase ≤ 3x ULN (upper limit of normal)in the absence of liver or bone metastases or ≤5 ULN(in patients with documented bone or liver metastases) * Serum transaminases (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\]) ≤ 2.5 x ULN in the absence of liver metastases or =\< 5 ULN in case of liver metastases) * Total bilirubin ≤1.5 x ULN * Glomerular Filtration Rate ≥ 60 mL/min (according to Modification of the Diet in Renal Disease (MDRD) formula or cockroft & Gault formula) * Serum albumin ≥ 30 g/L * Effective contraception during the study period and for 3 months after the last study treatment administration (male and female patient)
Exclusion criteria
* Patients having Central Nervous System (CNS) metastases. Patients who have had brain metastases surgically removed or irradiated with no residual disease confirmed by imaging are allowed * Documented EGFR activating mutations (if already tested) * Prior history of other malignancy except: * Basal cell carcinoma of the skin * Cervical intra epithelial neoplasia * Other cancer curatively treated with no evidence of disease for at least 5 years * Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) for a period of at least 4 weeks and whose treatment was not stopped 1 week prior to the start of the study treatment (i.e., D1 of Cycle 1) * Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence in the serum of the antigens HBs * Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes) * Patient with major surgery or radiotherapy within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1). Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted * Patient with an organ allograft * Known allergy to eggs, gentamicin or platinum-containing compounds * Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1) * Patient unable or unwilling to comply with the protocol requirements * Pregnancy or lactation * Bevacizumab will be allowed for patients with non-squamous carcinoma. Prescribing information must be followed and precautions have to be taken into consideration (e.g., patients having presented a serious hemorrhage or recent hemoptysis should not receive bevacizumab).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 2: Progression-free Survival (PFS) | Approximately 15 months | PFS is measured from date of randomization to radiographically documented progression according to RECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow-up will be censored at the date of their last radiographic assessment. |
| Phase 3: Overall Survival (OS) | Approximately 27 months | OS is measured from date of randomization to date of death from any cause. |
Secondary
| Measure | Time frame |
|---|---|
| Phase 3: Progression-free Survival (PFS) | Approximately 27 months |
| Phase 3 : Overall Response Rate (ORR) | Approximately 27 months |
| Phase 2 : Duration of response | Approximately 15 months |
| Phase 2 : Overall Survival (OS) | Approximately 15 months |
| Phase 3: Duration of response | Approximately 27 months |
| Phase 3: Safety | Approximately 27 months |
| Phase 2: Safety | Approximately 15 months |
| Phase 2 : Overall Response Rate (ORR) | Approximately 15 months |
Countries
Belgium, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom, United States
Outcome results
None listed